Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:35 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
NCT05609812 · Vera Therapeutics, Inc. · PHASE3 · withdrawn · last registry update 2025-05-23 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns.” | – | Registry record, Vera Therapeutics, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNFSF13B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-04-20Results posted on the registry: Washington University School of Medicine, Belimumab (NCT03207958)
- 2025-11-14Results posted on the registry: GlaxoSmithKline, Belimumab + Standard of care (NCT05917288)
- 2025-07-23Results posted on the registry: GlaxoSmithKline, Belimumab + Standard therapy (NCT04908865)
- 2024-12-04Phase 3 first posted: GlaxoSmithKline, Belimumab (NCT06716606)
- 2024-09-24Results posted on the registry: Amgen, Rozibafusp Alfa + Placebo for Rozibafusp Alfa (NCT04058028)
- 2024-08-27Phase 3 first posted: GlaxoSmithKline, Belimumab (NCT06572384)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision